AKT1 and head and neck squamous cell carcinoma: Thus, blocking the PI3K/AKT pathway with BYL719 enhanced trametinib efficacy, and the BYL719/trametinib combination showed superior antitumor activity in HNSCC cell lines, PDXs, and in a syngeneic murine HNSCC model.